JPMorgan Chase & Co. Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Key Points

• JPMorgan raised Heartflow’s price target from $35 to $45 and maintained an “overweight” rating, implying 10.81% upside from the prior close. The broader analyst consensus is “Moderate Buy,” with a $43.43 average target.
• Heartflow’s latest results exceeded expectations: the company reported a $0.07 per-share loss versus the expected $0.22 loss, while revenue rose 47.7% year over year to $64.08 million.
• Despite strong growth and a stock price near its 52-week high, Heartflow remains unprofitable, with analysts expecting a full-year loss of about $0.82 per share. Insiders have also sold 115,805 shares worth roughly $3.5 million over the past three months.

Heartflow (NASDAQ:HTFL - Get Free Report) had its price target increased by investment analysts at JPMorgan Chase & Co. from $35.00 to $45.00 in a report issued on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 10.81% from the company's previous close.

A number of other analysts also recently issued reports on HTFL. Robert W. Baird set a $45.00 target price on Heartflow in a research note on Friday. Weiss Ratings upgraded shares of Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an "overweight" rating in a research report on Friday. Piper Sandler reiterated an "overweight" rating and issued a $45.00 price objective on shares of Heartflow in a research report on Friday. Finally, Freedom Capital raised Heartflow to a "strong-buy" rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.43.

Heartflow Price Performance

NASDAQ HTFL traded up $9.60 during trading hours on Friday, hitting $40.61. 5,853,545 shares of the company's stock traded hands, compared to its average volume of 1,448,343. The company has a market capitalization of $3.50 billion and a PE ratio of -13.13. Heartflow has a 52-week low of $20.13 and a 52-week high of $42.95. The firm's 50-day moving average is $28.80 and its 200-day moving average is $27.70.

Heartflow (NASDAQ:HTFL - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. The business's revenue was up 47.7% compared to the same quarter last year. Equities research analysts predict that Heartflow will post -0.82 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO John C.M. Farquhar sold 38,900 shares of the firm's stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the completion of the transaction, the chief executive officer directly owned 457,935 shares in the company, valued at $16,027,725. This trade represents a 7.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $28.34, for a total transaction of $261,266.46. Following the sale, the insider directly owned 78,731 shares in the company, valued at $2,231,236.54. This represents a 10.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 115,805 shares of company stock worth $3,530,609. 7.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Heartflow

Hedge funds have recently bought and sold shares of the stock. TrueMark Investments LLC grew its position in shares of Heartflow by 1.4% during the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company's stock worth $654,000 after buying an additional 379 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow in the fourth quarter worth approximately $27,000. Strs Ohio grew its holdings in Heartflow by 35.3% during the 1st quarter. Strs Ohio now owns 4,600 shares of the company's stock worth $112,000 after acquiring an additional 1,200 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Heartflow in the 4th quarter valued at approximately $45,000. Finally, Legal & General Group Plc acquired a new stake in shares of Heartflow in the 3rd quarter valued at $59,000.

Heartflow News Summary

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Strong Q2 performance: Heartflow reported a loss of $0.07 per share, beating the $0.22 expected loss by $0.15. Revenue reached $64.08 million, an increase of 47.7% from the prior-year quarter. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Raised 2026 outlook: Management now expects full-year revenue of $246 million to $250 million, well above the approximately $230.1 million analyst consensus. The higher forecast reinforces expectations for continued demand for Heartflow’s AI-based coronary artery disease diagnostic technology.
• Positive Sentiment: Analyst upgrade: Stifel Nicolaus raised its price target from $40 to $45 and upgraded the stock to “Buy,” implying additional upside based on the reported reference price. This adds further momentum following the earnings release. Benzinga
• Neutral Sentiment: Profitability remains a concern: Although the quarterly loss was narrower than expected and significantly improved from the prior year, Heartflow remains unprofitable. Analysts currently expect a full-year loss of approximately $0.82 per share.
• Negative Sentiment: CEO stock sale: Chief Executive John C.M. Farquhar sold 22,562 shares valued at approximately $638,730, reducing his direct holdings by 4.92%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value, but repeated insider selling could still weigh modestly on sentiment. Heartflow CEO Sells Shares

Heartflow Company Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source